🔗 Share this article

While the US undertakes unprecedented revisions to its vaccination schedules, a particular individual appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by questioning Covid vaccinations during the global health crisis and has focused upon alleged deaths following Covid immunization in her recent tenure at the FDA.

Planned Changes to Childhood Immunization Program

Health officials had intended to unveil sweeping changes to the childhood immunization program earlier this month, bringing the US with Denmark’s national calendar, sources say – a major change that would put the US out of step with many the international standard with no evidence for public health gain. The planned update has been delayed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to speak at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the office this year.

A New Direction at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a greater focus upon dismantling long-standing immunizations at the FDA.

The new acting director has repeatedly called for halting specific childhood shot schedules in the US in order to be more in line with Denmark, a society with comprehensive healthcare and a population about the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – typically the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Expertise

The appointee has no obvious background in medication creation, approval processes or administrative roles, which has been typical for past directors of the CBER. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the CDER, said Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a major agency. She is not an expert in industry regulation.”

Previous commissioners of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

CDER has an enormous portfolio at the FDA, she stated.

“The public just pays attention on the novel medication approvals, but the generic drug division clears numerous off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and so forth, and every single one need to be managed,” Dr. Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant leadership component to the job, which manages more than 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” she said.

Official Statement and Controversial Policies

Regarding concerns about Høeg’s qualifications and whether this assignment indicates more teamwork among FDA leaders on vaccines, a press secretary stated that the “questions stem from inaccurate presumptions”.

“Her resume is consistent with the responsibilities of her role,” the official stated, citing the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed rapid medication authorization process that apparently troubled her predecessors. “How are these therapies being selected for this expedited pathway? Who takes the calls?” Howard said. “There is a lot of lack of transparency going on at the agency right now.”

In general, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent oversight of all drugs, with the exception of vaccines.”

Documented Past Work on Immunizations

With immunizations, Høeg has a more established, if troubling, track record, some experts have noted. She released a analysis using non-validated crowd-sourced reports to estimate the frequency of heart inflammation following COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the new administration included changing rules for new vaccines and discontinuing “unnecessary” immunizations, she stated after the election on a audio program. At the FDA, Høeg has reportedly proposed excluding adolescent males from receiving COVID-19 vaccines.

“She’s an thorough dogmatist who starts off with her beliefs and reverse-engineers to accommodate the science in a extremely deceptive, untruthful fashion,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|